Compare New York Times Co (NYT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Spyre Therapeutics Inc. Common Stock — how do they compare? New York Times Co trades at $67.15 (market cap $10.79B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.38% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NYT | SYRE | |
|---|---|---|
Market Cap | $10.79B | $7.52B |
Volume | 2,034,872 | 1,441,031 |
Sector | Media | Health |
52-Week High | $85.86 | $108.92 |
52-Week Low | $54.86 | $22.18 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $10.18B | $6.52B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.15, up 1.62% on the day, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82 billion in 2025, with net income reaching $344 million and a 12.17% margin. The company has beaten earnings estimates for the last three quarters, and analysts set a consensus price target of $81.50. Recent news includes a dividend declaration and ongoing litigation related to AI copyright issues.
Outlook is mixed: solid earnings growth and profitability support upside, but technical indicators and a shareholder lawsuit pose near-term risks. The stock offers value if it can maintain its growth trajectory, though investors should monitor legal developments and market sentiment closely.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
